6505--Emergency Pluvicto and Lutathera

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

262-NETWORK CONTRACT OFFICE 22 (36C262)

Contract Value

Not provided

Codes & Classification
Solicitation Number

6912710440008

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents2
The Department of Veterans Affairs, through its 262-Network Contract Office 22, has issued an award notice for the emergency procurement of Pluvicto and Lutathera, as indicated by the notice title "6505--Emergency Pluvicto and Lutathera." This procurement falls under the North American Industry Classification System (NAICS) code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further classified under Product Service Code 6505, denoting drugs and biologicals. The primary objective of this procurement is to ensure the timely and reliable supply of Pluvicto and Lutathera, both of which are specialized pharmaceutical products used in the treatment of certain cancers. The emergency nature of this acquisition underscores the critical need for these medications, likely to support ongoing patient care within the Veterans Affairs healthcare system. The intended outcome is to maintain uninterrupted access to these life-saving therapies for eligible veterans, thereby supporting the VA’s mission to provide high-quality medical care to those who have served. The contracting activity is managed by the 262-Network Contract Office 22, a federal office within the Department of Veterans Affairs. The primary point of contact for this procurement is Hestia Sim, who can be reached via email at [email protected] for any inquiries related to the award. The notice remains active as of the posting date, October 29, 2026, and further details, including attachments, can be accessed through the official SAM.gov opportunity listing (Opportunity ID: 3d2029d5692e4eab9822ccac36bb5d18). While the notice is classified as an award notice, specific details regarding the awarded contractor, contract value, period of performance, and set-aside requirements are not provided in the available information. There is also no indication of special considerations such as small business preferences or unique delivery requirements. However, the classification codes and the emergency designation suggest that the procurement was conducted to address an urgent and immediate need for these pharmaceutical products. Contractors specializing in the manufacturing or distribution of pharmaceutical preparations, particularly those with experience in supplying oncology medications to federal healthcare entities, may find this type of opportunity aligns with their capabilities. The procurement emphasizes the importance of compliance with federal standards for drug supply and the ability to respond rapidly to emergent healthcare needs. For further information or to review the official documentation and attachments associated with this award, interested parties are encouraged to visit the SAM.gov opportunity page linked in the notice.